ETF今日收评 | 稀有金属ETF涨超3% 创新药、黄金相关ETF跌超2%

Market Overview - The market is experiencing weakness with the Shanghai Composite Index opening lower and declining further, while the Shenzhen Component and ChiNext indices saw a slight reduction in their losses towards the end of the trading session [1] - There is rapid rotation of market hotspots, with the lithium battery industry chain experiencing a collective surge, the Fujian sector maintaining strength, and AI application concepts gaining momentum [1] ETF Performance - Rare metals ETFs showed significant gains, with the following performances: - 159608.SZ Rare Metals ETF increased by 3.68% - 562800.SH Rare Metals ETF rose by 3.66% - 561800.SH Rare Metals ETF Fund up by 3.22% [2] Industry Insights - Analysts suggest that the limited reserves of strategic minor metals, along with high extraction difficulties and insufficient supply elasticity, are leading to intensified supply-demand conflicts due to rapid growth in downstream demand from sectors like new energy, semiconductors, and military industry [3] - The ongoing scarcity of resources, upgrading demand structure, and policy adjustments are expected to drive rare metal prices upward, benefiting companies with resource reserves, technological barriers, and compliant export channels [3] Declining Sectors - The innovative pharmaceutical sector and gold-related ETFs have seen declines, with the following notable drops: - 589720.SH Innovative Drug ETF down by 2.7% - 159562.SZ Gold Stock ETF decreased by 2.57% [4][5] Biotechnology Developments - The biotechnology sector in China is witnessing positive developments, with multiple innovative drug companies having 35 studies selected for oral presentations at the ESMO 2025 conference, setting a new record [5] - Significant collaborations are emerging, such as the partnership between Innovent Biologics and Takeda, valued at up to $11.4 billion, reflecting global market recognition of the value of Chinese innovative drugs [5]